Clinical trial
Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome
NCT00452725 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00452725 |
|---|---|
| Title | Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome |
| Official title | Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Noonan Syndrome |
| Intervention type | Drug |
| Interventions | MAXOMAT ®, biosynthetic growth hormone |
| Enrollment | 36 |
| Start date | Oct 1, 1997 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Mar 27, 2007 |
| Last update posted | Oct 5, 2010 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: